Award

Combined anti-cancer immunotherapy based on the ability of immune responses in aged hosts

Description: The in vivo growth of murine colon carcinoma CT26 was more rapid in aged mice compared to young mice, and the serum levels of IL-6 were elevated in aged mice. In addition, aged mice showed lower response to anti-cancer vaccine by inactivated cancer cells compared to young mice. On the other hand, we examined the immune responses to murine renal carcinoma RENCA expressing human CA9 (hCA9) as a non-self antigen. As a result, young mice rejected RENCA/hCA9 and human CA9-recognizing CD8+ T cells and CD4+ T cells were induced in such mice. In addition, aged mice allowed RENCA/hCA9 to grow in vivo but combined immunotherapy with immune checkpoint blockade therapy with chemotherapy exerted significant antitumor effects even in aged mice.
Amount: ¥4,810,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2017-04-01
End date: 2020-03-31
Investigator: Mamoru Harada (lead)
Institution: Shimane University
Subfield: Immunology
Funded outputs count: 10
Funder award ID: 17K07217
OpenAlex ID: G786299790
2021 · Mamoru Harada, Yuichi Iida, et al. · Cancer Immunology Immunotherapy · 5
2020 · Takahito Taniura, Yuichi Iida, et al. · Cancer Science · 41
2020 · Yusuke Satoh, Hitoshi Kotani, et al. · Cancer Science · 63
2020 · Tamio Okimoto, Hitoshi Kotani, et al. · Cancer Science · 33
2020 · Ryosuke Tanino, Yoshihiro Amano, et al. · Molecular Cancer Therapeutics · 117